NCT00743938 - A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC | Biotech Hunter

Enrollment

141

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

June 30, 2012

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

BMS-690514

Tablets, Oral, 200 mg, once daily, Until disease progression or toxicity

DRUG

Erlotinib

Capsules, Oral, 150 mg, once daily, Until disease progression or toxicity

Trial Locations (30)

100

Local Institution, Taipei

112

Local Institution, Taipei

1900

Local Institution, La Plata

5300

Local Institution, La Rioja

10065

Memorial Sloan Kettering Cancer Center, New York

13915

Local Institution, Marseille

18512

Hema/Oncology Assoc. Of Nepa, Dunmore

27103

Piedmont Hematology Oncology Associates, Pllc, Winston-Salem

28046

Local Institution, Madrid

29605

Cancer Center Of The Carolinas, Greenville

31052

Local Institution, Toulouse

48903

Local Institution, Vizcaya

67000

Local Institution, Strasbourg

69373

Local Institution, Lyon

94800

Local Institution, Villejuif

97239

Oregon Health & Science University, Portland

06520

Yale University School Of Medicine, New Haven

06902-3628

Hematology Oncology, P.C., Stamford

02114

Mass General Hospital, Boston

48202-2689

Henry Ford Hospital, Detroit

Unknown

Local Institution, Bahía Blanca

Local Institution, Buenos Aires

X5000AAI

Local Institution, Córdoba

H3T 1E2

Local Institution, Montreal

J1H 5N4

Local Institution, Sherbrooke

05-400

Local Institution, Otwock

410-769

Local Institution, Gyeonggi-do

135-710

Local Institution, Seoul

138-736

Local Institution, Seoul

08035

Local Institution, Barcelona